{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:13:08Z","timestamp":1792077188970,"version":"4.4.0"},"reference-count":104,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"3","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U01 AI174997"],"award-info":[{"award-number":["U01 AI174997"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,15]]},"DOI":"10.14797\/mdcvj.1596","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T02:32:52Z","timestamp":1747276372000},"page":"40-50","source":"Crossref","is-referenced-by-count":8,"title":["Immunosuppression Management in Heart Transplantation"],"prefix":"10.14797","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-9822","authenticated-orcid":false,"given":"Marlena","family":"Habal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"key":"key20250515074211_B1","article-title":"The behaviour and fate of skin autografts and skin homografts in rabbits: A report to the War Wounds Committee of the Medical Research Council","volume":"78","year":"1944","journal-title":"J Anat"},{"issue":"4379","key":"key20250515074211_B2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/172603a0","article-title":"Actively acquired tolerance of foreign cells","volume":"172","year":"1953","journal-title":"Nature"},{"issue":"7","key":"key20250515074211_B3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s002680010124","article-title":"History of clinical transplantation","volume":"24","year":"2000","journal-title":"World J Surg"},{"issue":"3","key":"key20250515074211_B4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00000658-196209000-00002","article-title":"Kidney transplantation in modified recipients","volume":"156","year":"1962","journal-title":"Ann Surg"},{"key":"key20250515074211_B5","first-page":"385","article-title":"The Reversal of Rejection in Human Renal Homografts with Subsequent Development of Homograft Tolerance","volume":"117","year":"1963","journal-title":"Surg Gynecol Obstet"},{"issue":"443","key":"key20250515074211_B6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/pgmj.38.443.528","article-title":"Homologous human kidney transplantation. Experience with six patients","volume":"38","year":"1962","journal-title":"Postgrad Med J"},{"issue":"2","key":"key20250515074211_B7","first-page":"301","article-title":"The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation","volume":"124","year":"1967","journal-title":"Surg Gynecol Obstet"},{"issue":"4","key":"key20250515074211_B8","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1073\/pnas.56.4.1130","article-title":"Nature and mode of action of antilymphocytic antiserum","volume":"56","year":"1966","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"key20250515074211_B9","first-page":"457","article-title":"What we have learned about heart transplants","volume":"56","year":"1968","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"key20250515074211_B10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCULATIONAHA.117.029753","article-title":"Honoring 50 Years of Clinical Heart Transplantation in Circulation: In-Depth State-of-the-Art Review","volume":"137","year":"2018","journal-title":"Circulation"},{"key":"key20250515074211_B11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-5223(99)70375-2","article-title":"Thirty years of cardiac transplantation at Stanford University","volume":"117","year":"1999","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8151","key":"key20250515074211_B12","first-page":"1033","article-title":"Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers","volume":"2","year":"1979","journal-title":"Lancet"},{"issue":"1-2","key":"key20250515074211_B13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0041-1345(96)00327-2","article-title":"Multicenter evaluation of immunosuppressive regimens in heart transplantation. The Collaborative Transplant Study","volume":"29","year":"1997","journal-title":"Transplant Proc"},{"issue":"14","key":"key20250515074211_B14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM198310063091401","article-title":"A randomized clinical trial of cyclosporine in cadaveric renal transplantation","volume":"309","author":"Canadian Multicentre Transplant Study Group","year":"1983","journal-title":"N Engl J Med"},{"issue":"4605","key":"key20250515074211_B15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1126\/science.6407111","article-title":"Drug Transforms Transplant Medicine","volume":"221","year":"1983","journal-title":"Science"},{"key":"key20250515074211_B16","first-page":"582","article-title":"Allorecognition by T Lymphocytes and Allograft Rejection","volume":"7","year":"2016","journal-title":"Front Immunol"},{"key":"key20250515074211_B17","first-page":"368","year":"2016","edition":"1st"},{"key":"key20250515074211_B18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.iy.11.040193.002125","article-title":"The molecular basis of allorecognition","volume":"11","year":"1993","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"key20250515074211_B19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.immuni.2025.01.008","article-title":"Identification of indirect CD4(+ T cell epitopes associated with transplant rejection provides a target for donor-specific tolerance induction","volume":"58","year":"2025","journal-title":"Immunity"},{"issue":"5","key":"key20250515074211_B20","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.coi.2008.06.009","article-title":"The importance of the indirect pathway of allorecognition in clinical transplantation","volume":"20","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"key20250515074211_B21","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.4049\/jimmunol.177.11.7715","article-title":"B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection","volume":"177","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"key20250515074211_B22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.healun.2018.01.1291","article-title":"The management of antibodies in heart transplantation: An ISHLT consensus document","volume":"37","year":"2018","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"key20250515074211_B23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1600-6143.2011.03976.x","article-title":"Summary of the US FDA approval of belatacept","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"issue":"3","key":"key20250515074211_B24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.immuni.2017.09.001","article-title":"The IRF4 Gene Regulatory Module Functions as a Read-Write Integrator to Dynamically Coordinate T Helper Cell Fate","volume":"47","year":"2017","journal-title":"Immunity"},{"issue":"3","key":"key20250515074211_B25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","article-title":"Incidence and impact of de novo donor-specific alloantibody in primary renal allografts","volume":"95","year":"2013","journal-title":"Transplantation"},{"issue":"3","key":"key20250515074211_B26","article-title":"Routine screening for HLA Antibodies in Heart Transplant patients-Does it affect clinical decision making?","volume":"38","year":"2024","journal-title":"Clin Transplant"},{"issue":"8","key":"key20250515074211_B27","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/01.tp.0000180564.14050.49","article-title":"The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome","volume":"80","year":"2005","journal-title":"Transplantation"},{"issue":"6","key":"key20250515074211_B28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/01.tp.0000281918.51138.3f","article-title":"Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children","volume":"84","year":"2007","journal-title":"Transplantation"},{"issue":"4","key":"key20250515074211_B29","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/ajt.16333","article-title":"T cell repertoire analysis suggests a prominent bystander response in human cardiac allograft vasculopathyk","volume":"21","year":"2021","journal-title":"Am J Transplant"},{"issue":"12","key":"key20250515074211_B30","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1111\/j.1600-6143.2012.04269.x","article-title":"Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"issue":"25","key":"key20250515074211_B31","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+ T cell exhaustion","volume":"116","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"key20250515074211_B32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.healun.2021.07.015","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report - 2021; Focus on recipient characteristics","volume":"40","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"key20250515074211_B33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007890-199808270-00016","article-title":"A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators","volume":"66","year":"1998","journal-title":"Transplantation"},{"issue":"5","key":"key20250515074211_B34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.healun.2005.02.002","article-title":"2005 Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients","volume":"24","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"key20250515074211_B35","article-title":"Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: A systematic review","volume":"35","year":"2021","journal-title":"Transplant Rev (Orlando)"},{"issue":"12","key":"key20250515074211_B36","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.healun.2017.10.009","article-title":"Clinical trials in heart transplantation: The evolution of evidence in immunosuppression","volume":"36","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"key20250515074211_B37","first-page":"2459","article-title":"Consensus Conference on Heart-Kidney Transplantation","year":"2021"},{"issue":"8","key":"key20250515074211_B38","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/tri.12940","article-title":"Renal function at 1 year after cardiac transplantation but not acute kidney injury is highly associated with long-term survival and loss of renal function - a retrospective cohort study","volume":"30","year":"2017","journal-title":"Transplant Int"},{"issue":"9","key":"key20250515074211_B39","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","article-title":"Cardiovascular toxicities of immunosuppressive agents","volume":"2","year":"2002","journal-title":"Am J Transplant"},{"issue":"10","key":"key20250515074211_B40","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.healun.2019.08.004","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match","volume":"38","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"7","key":"key20250515074211_B41","first-page":"1338","article-title":"Cardiac Allograft Vasculopathy: The Enduring Enemy of Cardiac Transplantation Transplantation","volume":"103","year":"2019"},{"issue":"8","key":"key20250515074211_B42","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1111\/ajt.12809","article-title":"Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial","volume":"14","year":"2014","journal-title":"Am J Transplant"},{"issue":"5","key":"key20250515074211_B43","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ajt.12181","article-title":"Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial","volume":"13","year":"2013","journal-title":"Am J Transplant"},{"issue":"6","key":"key20250515074211_B44","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1600-6143.2006.01290.x","article-title":"Tacrolimus with mycophenolate mofetil MMF or sirolimus vs cyclosporine with MMF in cardiac transplant patients: 1-year report","volume":"6","year":"2006","journal-title":"Am J Transplant"},{"issue":"1","key":"key20250515074211_B45","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/TP.0000000000002702","article-title":"Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study","volume":"104","year":"2020","journal-title":"Transplantation"},{"key":"key20250515074211_B46","article-title":"Comparing everolimus-based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from six months after heart transplantation: the randomized MANDELA study","year":"2019","journal-title":"Am J Transplant"},{"issue":"6","key":"key20250515074211_B47","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacc.2017.12.005","article-title":"Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients","volume":"71","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20250515074211_B48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ajt.16155","article-title":"Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients","volume":"21","year":"2021","journal-title":"Am J Transplant"},{"issue":"24","key":"key20250515074211_B49","first-page":"02027","article-title":"Incidence and risk factors for rejection after conversion from calcineurin inhibitor to sirolimus-based immunosuppression in orthotopic heart transplant recipients","volume":"S1053-2498","year":"2024","journal-title":"J Heart Lung Transplant"},{"issue":"17","key":"key20250515074211_B50","article-title":"Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database","volume":"11","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"key20250515074211_B51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2018.03.111","article-title":"Outcomes associated with mammalian target of rapamycin mTOR inhibitors in heart transplant recipients: A meta-analysis","volume":"265","year":"2018","journal-title":"Int J Cardiol"},{"issue":"1","key":"key20250515074211_B52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2013.11.036","article-title":"Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?","volume":"171","year":"2014","journal-title":"Int J Cardiol"},{"issue":"5","key":"key20250515074211_B53","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/ajt.14544","article-title":"Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection","volume":"18","year":"2018","journal-title":"Am J Transplant"},{"issue":"7","key":"key20250515074211_B54","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.1701259","article-title":"HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection","volume":"200","year":"2018","journal-title":"J Immunol"},{"issue":"4","key":"key20250515074211_B55","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1172\/JCI66204","article-title":"Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells","volume":"123","year":"2013","journal-title":"J Clin Invest"},{"key":"key20250515074211_B56","article-title":"Early Everolimus Initiation Fails to Counteract the Cytotoxic Response Mediated by CD8(+ T and NK Cells in Heart Transplant Patients","volume":"9","year":"2018","journal-title":"Front Immunol"},{"issue":"12","key":"key20250515074211_B57","first-page":"4472","article-title":"T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression","volume":"7","year":"1987","journal-title":"Mol Cell Biol"},{"issue":"4902","key":"key20250515074211_B58","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.2540528","article-title":"Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway","volume":"244","year":"1989","journal-title":"Science"},{"issue":"4","key":"key20250515074211_B59","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1073\/pnas.86.4.1333","article-title":"CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines\/cytokines","volume":"86","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"key20250515074211_B60","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.4049\/jimmunol.144.5.1646","article-title":"CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes","volume":"144","year":"1990","journal-title":"J Immunol"},{"issue":"3","key":"key20250515074211_B61","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","year":"2005","journal-title":"Am J Transplant"},{"issue":"Suppl 2","key":"key20250515074211_B62","first-page":"S21","article-title":"The evolving clinical profile of abatacept CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis","volume":"7 Suppl 2","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"key20250515074211_B63","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation","volume":"353","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"key20250515074211_B64","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors BENEFIT-EXT study)","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"key20250515074211_B65","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients BENEFIT study)","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"issue":"4","key":"key20250515074211_B66","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and Long-Term Outcomes in Kidney Transplantation","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"key20250515074211_B67","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/ajt.14721","article-title":"De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies","volume":"18","year":"2018","journal-title":"Am J Transplant"},{"key":"key20250515074211_B68","unstructured":"ATC [Internet]. Mount Laurel, NJ: American Transplant Congress; c2025. Everly M, Jucaud V, Roberts M, Gebel HM, Bray RA. Immunogenic HLA Mismatches and Evidence That Belatacept May Be the First Therapy Able to Prevent DQ De Novo DSA: An Analysis of the BENEFIT and BENEFIT-EXT Trial Cohorts; 2017 suppl 3 [cited 2025 Apr 27]. Available from: https:\/\/atcmeetingabstracts.com\/abstract\/immunogenic-hla-mismatches-and-evidence-that-belatacept-may-be-the-first-therapy-able-to-prevent-dq-de-novo-dsa-an-analysis-of-the-benefit-and-benefit-ext-trial-cohorts\/"},{"issue":"7","key":"key20250515074211_B69","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/ajt.14738","article-title":"Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT","volume":"18","year":"2018","journal-title":"Am J Transplant"},{"issue":"8","key":"key20250515074211_B70","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/TP.0000000000001253","article-title":"Tracing Donor-MHC Class II Reactive B cells in Mouse Cardiac Transplantation: Delayed CTLA4-Ig Treatment Prevents Memory Alloreactive B-Cell Generation","volume":"100","year":"2016","journal-title":"Transplantation"},{"issue":"8","key":"key20250515074211_B71","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/ajt.13761","article-title":"Delayed Cytotoxic T Lymphocyte-Associated Protein 4-Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"issue":"10","key":"key20250515074211_B72","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1097\/TP.0000000000001589","article-title":"Belatacept Compared With Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study","volume":"101","year":"2017","journal-title":"Transplantation"},{"issue":"11","key":"key20250515074211_B73","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1111\/ajt.14353","article-title":"Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function","volume":"17","year":"2017","journal-title":"Am J Transplant"},{"issue":"10","key":"key20250515074211_B74","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1097\/TP.0000000000001755","article-title":"A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation","volume":"101","year":"2017","journal-title":"Transplantation"},{"issue":"8","key":"key20250515074211_B75","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study","volume":"14","year":"2014","journal-title":"Am J Transplant"},{"key":"key20250515074211_B76","article-title":"Biopsy-Proven T-Cell Mediated Rejection After Belatacept Rescue Conversion: A Multicenter Retrospective Study","volume":"37","year":"2024","journal-title":"Transpl Int"},{"issue":"5","key":"key20250515074211_B77","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2215\/CJN.0000000000000411","article-title":"Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients","volume":"19","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"key20250515074211_B78","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ajt.15584","article-title":"Belatacept-based immunosuppression: A calcineurin inhibitor-sparing regimen in heart transplant recipients","volume":"20","year":"2020","journal-title":"Am J Transplant"},{"issue":"1","key":"key20250515074211_B79","article-title":"De Novo Belatacept in a Kidney-After-Heart Transplant Recipient","volume":"6","year":"2019","journal-title":"Transplant Direct"},{"issue":"5","key":"key20250515074211_B80","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.immuni.2016.04.012","article-title":"T Cell Cosignaling Molecules in Transplantation","volume":"44","year":"2016","journal-title":"Immunity"},{"issue":"12","key":"key20250515074211_B81","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from Calcineurin Inhibitor to Belatacept-based Maintenance Immunosuppression in Renal Transplant Recipients: a Randomized Phase 3b Trial","volume":"32","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"key20250515074211_B82","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/ajt.16132","article-title":"CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept","volume":"21","year":"2021","journal-title":"Am J Transplant"},{"issue":"5","key":"key20250515074211_B83","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/ajt.16386","article-title":"Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients","volume":"21","year":"2021","journal-title":"Am J Transplant"},{"issue":"2","key":"key20250515074211_B84","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ajt.2023.09.011","article-title":"Belatacept with time-limited tacrolimus coimmunosuppression modifies the 3-year risk of eplet mismatch in kidney transplantation","volume":"24","year":"2024","journal-title":"Am J Transplant"},{"issue":"9","key":"key20250515074211_B85","article-title":"Retrospective evaluation of the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: A single-center clinical experience","volume":"31","year":"2017","journal-title":"Clin Transplant"},{"issue":"9","key":"key20250515074211_B86","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.2400146","article-title":"Rapamycin Prevents Expansion of Costimulation Blockade-resistant CD8+ Alloreactive Memory Cells following Depletional Induction in Renal Transplant Recipients","volume":"213","year":"2024","journal-title":"J Immunol"},{"issue":"4","key":"key20250515074211_B87","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41581-023-00791-0","article-title":"Translating B cell immunology to the treatment of antibody-mediated allograft rejection","volume":"20","year":"2024","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"key20250515074211_B88","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.4049\/jimmunol.2300363","article-title":"The Transplant Bellwether: Endothelial Cells in Antibody-Mediated Rejection","volume":"211","year":"2023","journal-title":"J Immunol"},{"issue":"8","key":"key20250515074211_B89","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ajt.2024.03.031","article-title":"Redefining the molecular rejection states in 3230 heart transplant biopsies: Relationships to parenchymal injury and graft survival","volume":"24","year":"2024","journal-title":"Am J Transplant"},{"key":"key20250515074211_B90","article-title":"Donor HLA-DQ reactive B cells clonally expand under chronic immunosuppression and include atypical CD21 low CD27 - B cells with high-avidity germline B-cell receptors","year":"2024","journal-title":"bioRxiv [Preprint]"},{"issue":"6","key":"key20250515074211_B91","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","article-title":"Germinal Center and Extrafollicular B Cell Responses in Vaccination, Immunity, and Autoimmunity","volume":"53","year":"2020","journal-title":"Immunity"},{"issue":"2","key":"key20250515074211_B92","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection","volume":"29","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"key20250515074211_B93","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1681\/ASN.2016070727","article-title":"Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients","volume":"28","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"key20250515074211_B94","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ajt.2022.11.001","article-title":"Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy","volume":"23","year":"2023","journal-title":"Am J Transplant"},{"issue":"10","key":"key20250515074211_B95","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/ajt.15881","article-title":"Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients","volume":"20","year":"2020","journal-title":"Am J Transplant"},{"issue":"20","key":"key20250515074211_B96","article-title":"Desensitization and belatacept-based maintenance therapy in pregnancy-sensitized monkeys receiving a kidney transplant","volume":"9","year":"2023","journal-title":"Sci Adv"},{"issue":"4","key":"key20250515074211_B97","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MOT.0000000000000656","article-title":"The past, present, and future of costimulation blockade in organ transplantation","volume":"24","year":"2019","journal-title":"Curr Opin Organ Transplant"},{"issue":"12","key":"key20250515074211_B98","article-title":"Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction","volume":"17","year":"2024","journal-title":"Circ Heart Fail"},{"issue":"2","key":"key20250515074211_B99","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection","volume":"391","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"key20250515074211_B100","article-title":"IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice","volume":"15","year":"2024","journal-title":"Nat Commun"},{"key":"key20250515074211_B101","first-page":"28","article-title":"Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts","volume":"22 Suppl 4","year":"2022","journal-title":"Am J Transplant"},{"issue":"10237","key":"key20250515074211_B102","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials","volume":"395","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"key20250515074211_B103","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cei\/uxac118","article-title":"The potential for Treg-enhancing therapies in transplantation","volume":"211","year":"2023","journal-title":"Clin Exp Immunol"},{"issue":"669","key":"key20250515074211_B104","article-title":"Selective decrease of donor-reactive T(regs after liver transplantation limits T(reg therapy for promoting allograft tolerance in humans","volume":"14","year":"2022","journal-title":"Sci Transl Med"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:40:49Z","timestamp":1787672449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1596\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5,15]]}},"alternative-id":["10.14797\/mdcvj.1596"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1596","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}